MASAHIRO KUROBE

Dr. MASAHIRO KUROBE

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2018 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
ETEi‐Ichiro Takaoka
Ei‐Ichiro Takaoka
MKMasahiro Kurobe
Masahiro Kurobe
HOHiroki Okada
Hiroki Okada
STShun Takai
Shun Takai
TSTakahisa Suzuki
Takahisa Suzuki
CCChristopher J. Chermansky
Christopher J. Chermansky

26 July 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
MKMASAHIRO KUROBE
MASAHIRO KUROBE
KKKoji Kawai
Koji Kawai
TOTakehiro Oikawa
Takehiro Oikawa
DIDaishi Ichioka
Daishi Ichioka
SKShuya Kandori
Shuya Kandori
HNHiroyuki Nishiyama
Hiroyuki Nishiyama
Purpose The purpose of the study was to assess the efficacy of TIP as salvage chemotherapy for germ cell tumor (GCT) patients with relapsed disease or cisplatin (CDDP)-refractory disease and consolidation chemotherapy for patients who responded unfavorably to first-line chemotherapy. Methods Forty-three patients with advanced GCT were treated with TIP. Eleven with relapsed disease and five with CDDP-refractory disease received TIP as salvage chemotherapy. The remaining 27 received TIP as consolidation chemotherapy following initial induction chemotherapy. All patients received prophylactic granulocyte colony-stimulating factor. Results In total, 116 cycles of TIP were administered with a median of three cycles (range 1–4 cycles) per patient. Before TIP, 33 patients showed elevated tumor marker and 23 patients (70 %) achieved marker normalization with the chemotherapy. One of six (17 %) patients with refractory disease and 5 of 10 (50 %) patients with relapsed disease achieved durable complete response (CR) after TIP with or without surgery. Eighteen of 27 (67 %) patients receiving TIP as consolidation chemotherapy achieved durable CR. Five additional patients were given further chemotherapy and achieved durable CR. Grade 4 leukocytopenia and thrombocytopenia were observed in 91 and 42 % of patients, respectively; all were managed with routine supportive care. Grade 2 and grade 3 sensory neuropathy was observed in 37 and 2 % of patients, respectively. Conclusions The TIP was effective for relapsed patients with favorable risk features and selected CDDP-refractory GCT patients. Results of TIP as consolidation for patients with unfavorable response to the initial chemotherapy were also encouraging. The toxicities were mainly myelosuppression and sensory neuropathy.

8 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMasahiro Kurobe
Masahiro Kurobe
TKTakahiro Kojima
Takahiro Kojima
KNKouichi Nishimura
Kouichi Nishimura
SKShuya Kandori
Shuya Kandori
TKTakashi Kawahara
Takashi Kawahara
HNHiroyuki Nishiyama
Hiroyuki Nishiyama
Oncogenic FGFR3-TACC3 fusions and FGFR3 mutations are target candidates for small molecule inhibitors in bladder cancer (BC). Because FGFR3 and TACC3 genes are located very closely on chromosome 4p16.3, detection of the fusion by DNA-FISH (fluorescent in situ hybridization) is not a feasible option. In this study, we developed a novel RNA-FISH assay using branched DNA probe to detect FGFR3-TACC3 fusions in formaldehyde-fixed paraffin-embedded (FFPE) human BC samples. The RNA-FISH assay was developed and validated using a mouse xenograft model with human BC cell lines. Next, we assessed the consistency of the RNA-FISH assay using 104 human BC samples. In this study, primary BC tissues were stored as frozen and FFPE tissues. FGFR3-TACC3 fusions were independently detected in FFPE sections by the RNA-FISH assay and in frozen tissues by RT-PCR. We also analyzed the presence of FGFR3 mutations by targeted sequencing of genomic DNA extracted from deparaffinized FFPE sections. FGFR3-TACC3 fusion transcripts were identified by RNA-FISH and RT-PCR in mouse xenograft FFPE tissues using the human BC cell lines RT112 and RT4. These cell lines have been reported to be fusion-positive. Signals for FGFR3-TACC3 fusions by RNA-FISH were positive in 2/60 (3%) of non-muscle-invasive BC (NMIBC) and 2/44 (5%) muscle-invasive BC (MIBC) patients. The results of RT-PCR of all 104 patients were identical to those of RNA-FISH. FGFR3 mutations were detected in 27/60 (45%) NMIBC and 8/44 (18%) MIBC patients. Except for one NMIBC patient, FGFR3 mutation and FGFR3-TACC3 fusion were mutually exclusive. We developed an RNA-FISH assay for detection of the FGFR3-TACC3 fusion in FFPE samples of human BC tissues. Screening for not only FGFR3 mutations, but also for FGFR3-TACC3 fusion transcripts has the potential to identify additional patients that can be treated with FGFR inhibitors.

1 November 2019 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
NWNaoki Wada
Naoki Wada
TSTakahiro Shimizu
Takahiro Shimizu
NSNobutaka Shimizu
Nobutaka Shimizu
MKMasahiro Kurobe
Masahiro Kurobe
WGWilliam C. de Groat
William C. de Groat
NYNaoki Yoshimura
Naoki Yoshimura
We investigated the involvement of brain-derived neurotrophic factor (BDNF) in bladder and urethral dysfunction using spinal cord-injured mice. We evaluated bladder and urethral function of female mice with 4-wk spinal cord injury (SCI) by filling cystometry and electromyography (EMG) of the external urethral sphincter (EUS) under a conscious condition. Anti-BDNF antibodies (10 μg·kg−1·h−1) were administered in some mice for 1 wk before the evaluation. Bladder and spinal (L6−S1) BDNF protein levels were examined by ELISA. Transcript levels of transient receptor potential channels or acid-sensing ion channels (Asic) in L6−S1 dorsal root ganglia were evaluated by RT-PCR. Voided volume and voiding efficiency were significantly increased without any changes in nonvoiding contractions, and the duration of reduced EMG activity during the voiding phase was significantly prolonged in anti-BDNF antibody-treated SCI mice. Compared with spinal cord-intact mice, SCI mice showed increased concentrations of bladder and spinal BDNF. Anti-BDNF antibody treatment decreased bladder and spinal BDNF protein concentrations of SCI mice. Asic2 and Asic3 transcripts were significantly increased after SCI but decreased after anti-BDNF antibody administration. These results indicate that upregulated expression of bladder and spinal BDNF is involved in the emergence of inefficient voiding in SCI mice. Thus, BDNF-targeting treatment could be an effective modality for the treatment of voiding problems, including inefficient voiding and detrusor sphincter dyssynergia after SCI.

30 June 2022 in Journal of the Mechanical Behavior of Biomedical Materials
Verified
Journal Article
Open access
FCFangzhou Cheng
Fangzhou Cheng
PWPaul N. Watton
Paul N. Watton
GPGiulia Pederzani
Giulia Pederzani
MKMasahiro Kurobe
Masahiro Kurobe
ETEi-Ichiro Takaoka
Ei-Ichiro Takaoka
ARAnne M. Robertson
Anne M. Robertson
We present a constrained mixture-micturition-growth (CMMG) model for the bladder. It simulates bladder mechanics, voiding function (micturition) and tissue adaptations in response to altered biomechanical conditions. The CMMG model is calibrated with both in vivo and in vitro data from healthy male rat urinary bladders (cystometry, bioimaging of wall structure, mechanical testing) and applied to simulate the growth and remodeling (G&R) response to partial bladder outlet obstruction (BOO). The bladder wall is represented as a multi-layered, anisotropic, nonlinear constrained mixture. A short time scale micturition component of the CMMG model accounts for the active and passive mechanics of voiding. Over a second, longer time scale, G&R algorithms for the evolution of both cellular and extracellular constituents act to maintain/restore bladder (homeostatic) functionality. The CMMG model is applied to a spherical membrane model of the BOO bladder utilizing temporal data from an experimental male rodent model to parameterize and then verify the model. Consistent with the experimental studies of BOO, the model predicts: an initial loss of voiding capacity followed by hypertrophy of SMC to restore voiding function; bladder enlargement; collagen remodeling to maintain its role as a protective sheath; and increased voiding duration with lower average flow rate.

3 October 2019 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
NSNobutaka Shimizu
Nobutaka Shimizu
NWNAOKI WADA
NAOKI WADA
TSTakahiro Shimizu
Takahiro Shimizu
TSTakahisa Suzuki
Takahisa Suzuki
MKMasahiro Kurobe
Masahiro Kurobe
NYNaoki Yoshimura
Naoki Yoshimura